The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study
Open accessAbstract
In hypoparathyroidism, plasma parathyroid hormone (PTH) levels are inadequate to maintain plasma calcium concentration within the reference range. On conventional treatment with calcium supplements and active vitamin D analogues, bone turnover is abnormally low, and BMD is markedly increased. We aimed to study the effects of PTH-replacement therapy (PTH-RT) on calcium-phosphate homeostasis and BMD. In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1–84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment. Compared with placebo, patients on PTH(1–84) reduced their daily dose of calcium and active vitamin D significantly by 75% and 73%, respectively, without developing hypocalcemia. However, hypercalcemia occurred frequently during the downtitration of calcium and active vitamin D. Plasma phosphate and renal calcium and phosphate excretion did not change. Compared with placebo, PTH(1–84) treatment significantly increased plasma levels of bone-specific alkaline phosphatase (+226% ± 36%), osteocalcin (+807% ± 186%), N-terminal propeptide of procollagen 1 (P1NP; +1315% ± 330%), cross-linked C-telopeptide of type 1 collagen (CTX; +1209% ± 459%), and urinary cross-linked N-telopeptide of type 1 collagen (NTX; (+830% ± 165%), whereas BMD decreased at the hip (−1.59% ± 0.57%), lumbar spine (−1.76% ± 1.03%), and whole body (−1.26% ± 0.49%) but not at the forearm. In conclusion, the need for calcium and active vitamin D is reduced significantly during PTH-RT, whereas plasma calcium and phosphate levels are maintained within the physiologic range. In contrast to the effect of PTH(1–84) treatment in patients with osteoporosis, PTH-RT in hypoparathyroidism causes a decrease in BMD. This is most likely due to the marked increased bone turnover. Accordingly, PTH-RT counteracts the state of overmineralized bone and, during long-term treatment, may cause a more physiologic bone metabolism. © 2011 American Society for Bone and Mineral Research
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071408 · Cited by 914
Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23
Bergwitz, C., & Jüppner, H. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.051308.111339 · Cited by 741
Overview of the FGF23-Klotho axis
Kuro-o, M. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1260-4 · Cited by 162
Cited by
Bollerslev, J., Rejnmark, L., Marcocci, C., Shoback, D. M., Sitges-Serra, A., van Biesen, W., & Dekkers, O. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0628 · Cited by 462
Self-citationManagement of Hypoparathyroidism: Summary Statement and Guidelines
Brandi, M. L., Bilezikian, J. P., Shoback, D., Bouillon, R., Clarke, B. L., Thakker, R. V., Khan, A. A., & Potts, J. T. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3907 · Cited by 436
Long-Term Follow-Up of Patients with Hypoparathyroidism
Mitchell, D. M., Regan, S., Cooley, M. R., Lauter, K. B., Vrla, M. C., Becker, C. B., Burnett-Bowie, S.-A. M., & Mannstadt, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1808 · Cited by 402
Presentation of Hypoparathyroidism: Etiologies and Clinical Features
Shoback, D. M., Bilezikian, J. P., Costa, A. G., Dempster, D., Dralle, H., Khan, A. A., Peacock, M., Raffaelli, M., Silva, B. C., Thakker, R. V., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3909 · Cited by 371
Sikjaer, T., Rolighed, L., Hess, A., Fuglsang-Frederiksen, A., Mosekilde, L., & Rejnmark, L. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2677-6 · Cited by 134
Self-citation
Metadata
- Authors
- Sikjaer, T., Rejnmark, L., Rolighed, L., Heickendorff, L., Mosekilde, L., & the Hypoparathyroid Study Group
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07-19
- Volume
- 26
- Issue
- 10
- Pages
- 2358-2370
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2039970252
- Cited by
- 188
- References
- 3
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study. https://app.cochat.ai/papers/10.1002/jbmr.470
- The paper
- Sikjaer, T., Rejnmark, L., Rolighed, L., Heickendorff, L., Mosekilde, L., & the Hypoparathyroid Study Group. (2011). The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.470
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.